Evaxion Biotech Investor Relations Material
Latest events
Q2 2025
Evaxion Biotech
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Evaxion Biotech A/S
Access all reports
Evaxion Biotech utilizes the AI platform, which is designed to reduce the identification of novel epitopes, and to develop neoantigens, vaccines, and antibody-based therapies; pNLS platform that is designed to identify novel protein structures through computational design; and 2D-to-3D structural similarity searching algorithm. It is developing EB023, a peptide based immunotherapy for the treatment of head and neck cancer. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.
Key slides for Evaxion Biotech A/S
Investor Update
Evaxion Biotech A/S
Investor Update
Evaxion Biotech A/S
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
EVAX
Country
🇺🇸 United States